Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing, and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections. The corporate headquarters is located in Copenhagen, Denmark and Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia’s four manufacturing facilities are located in China, Denmark, Hungary and in the U.S. With over 115 years of experience and with more than 1700 employees, Xellia is a world-leading trusted supplier of several important established anti-infective drugs. Supplying products to more than 70 countries worldwide and with more than 500 customers internationally, Xellia is the leading supplier of important anti-infectives vancomycin and colistimethate sodium (CMS). Xellia’s purpose is to save lives by leading the fight against infections. We work to achieve our goal by prioritizing the patient and through providing a strong and resilient supply of critical anti-infectives. Continuing the Company’s evolution, Xellia Pharmaceuticals focuses its R&D investments within inhalable and injectable product technologies, generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.